Medium impact
Electric Tumor Treatment Fields (CPB 0827, reviewed 2026-02-18)
Aetna·Effective Feb 18, 2026
HCPCS J8700 is officially defined as "Temozolomide, oral, 5 mg." HCPCS J8700 is referenced in 1 tracked payer policy change from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J8700 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Related
Get alerts for changes like this
Save a search and receive a daily digest whenever a new policy change matches your filters.